Slide 1: Orion Financial Review 1-12/2017
Orion Financial Review 1-12/2017
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion had a good centenary year
Orion had a good centenary year ● Net sales were at previous year’s level. 1-12/2016 1-12/2017 ● The operating profit in comparative period included 1,074 1,085 EUR 22 million of capital gains. ● Dexdor and Easyhaler product family continued to grow. ● Growth in sales of biosimilar Remsima generated
Slide 4: Geographical breakdown of net sales
Geographical breakdown of net sales 1-12/2017 Orion’s own sales network 15% 7% 31% 30% 1 17% Finland Scandinavia Other Europe North America ROW Financial Review 1–12/2017 © Orion Corporation 7 February 2018 4
Slide 5: Breakdown of net sales by business division
Breakdown of net sales by business division 3% 5% Net sales, 1-12/ 1-12/ 5% EUR million 2017 2016 Change 7% 32% Specialty Products 519 508 +2% Proprietary Products 351 350 0% 48% Animal Health 76 77 -2% Fermion 51 48 +7% Proprietary Products Specialty Products Contract Animal Health manufacturing &
Slide 6: Pharmaceuticals business
Pharmaceuticals business RION Building well-being
Slide 7: Best-selling pharmaceuticals 1-12/2017
Best-selling pharmaceuticals 1-12/2017 Net sales, Change vs. Product Indication EUR million 1-12/2016 1. Parkinson’s disease 104 -16% 2. Asthma, COPD 77 +20% 3. Intensive care sedative 64 +13% 4. Acute decompensated heart failure 57 +2% Rheumatoid arthritis, inflammatory 5. bowel diseases 57 +34% 6.
Slide 8: Proprietary Products
Proprietary Products ● As expected, sales of Stalevo, Comtess and Comtan Breakdown of net sales continued to decline, but growth in other products 7% compensated for the decline. 7% ● Budesonide-formoterol Easyhaler product has been 30% launched in all key European markets. 16% ● Sales of Dexdor gre
Slide 9: Parkinson's drugs
Parkinson’s drugs Sales, EUR million Sales of Orion’s branded 60 Parkinson’s drugs by 50 market area* 40 3% 30 38% 29% 20 10 0 Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4 2013 2014 2015 2016 2017 30% Europe Japan Orion sales Deliveries to Novartis ROW USA *Source: IMS Health sales statistics MAT9/2017 Fi
Slide 10: Easyhaler product family
Easyhaler product family Sales, EUR million ● Easyhaler product family sales grew by 20%, driven 25 by budesonide-formoterol Easyhaler, which grew by 46%. 20 ● Budesonide-formoterol Easyhaler has been launched 15 in all key European markets. 10 – Menarini is marketing budesonide-formoterol in Southe
Slide 11: Dexdor intensive care sedative
Dexdor intensive care sedative European sedative market Sales, EUR million MAT9/2017* 20 Total market value 18 EUR 537 million (+2%) 16 14 12% 12 10 12% 8 6 64% 4 12% 2 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Propofol EUR 345 million (-1%) 2013 2014 2015 2016 2017 Midazolam EUR 64
Slide 12: Specialty Products
Specialty Products Breakdown of net sales Net sales in key markets EUR vs. by market area 1-12/2017 million 1-12/2016 Finland 292 -2% 13% Scandinavia 94 +14% 13% Eastern Europe and Russia 65 +10% 56% ● Specialty Products net sales at similar level to previous year. ● 34% growth in sales of Remsima®
Slide 13: Orion strong in home market Finland
Orion strong in home market Finland Finnish human pharmaceuticals market 1-12/2017: Finland’s biggest pharmaceutical companies 1-12/2017, EUR million ● Wholesale EUR 2,378 million 350 294 300 ● Orion's market share 12% 250 ● Growth of total market was 2%, 200 Orion's sales decreased by 2% 143 150 11
Slide 14: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Project Indication PHASE Registration Bioequivalence Easyhaler® salmeterol-fluticasone Asthma, COPD Registration study Bioequivalence Easyhaler® tiotropium COPD study Darolutamide (ODM-201) 1) Prostate cancer (nmCRPC) I II III Darolutamide (ODM-201) 1
Slide 15: Diagnostics business
_ ee Diagnostics business S RION ing well-being Build
Slide 16: Orion Diagnostica
Orion Diagnostica ● Orion has decided to investigate the 1-12/2016 1-12/2017 possible sale of Orion Diagnostica or other transaction that would result in 55 54 transfer of Orion Diagnostica outside the Orion Group. ● Orion Diagnostica manufactures in vitro diagnostic tests and testing systems suitab
Slide 17: Orion's outlook
Orion’s outlook
Slide 18: Outlook for 2018
Outlook for 2018 Due to generic and price competition we estimate that in 2018 net sales will be at the same level or slightly lower than in 2017 (net sales were Net sales EUR 1,085 million in 2017). Orion continues persistent actions to generate growth. Due to the estimated sales development and th
Slide 19: Orion Calendar 2018
Orion Calendar 2018 Annual General Meeting 2018 20 March Interim Report 1-3/2018 24 April Half-Year Financial Report 18 July Interim Report 1-9/2018 24 October
Slide 20: Building well-being
Building well-being Building well-being